Exscientia: Drug Discovery Platform Attracting Partners And Cash
Morsa Images As Generative AI impacts drug research, this thesis aims to uncover the opportunities for Exscientia plc (NASDAQ:EXAI) and show it is a buy based on the strength of its technology platform. Noteworthily, I was again bullish when covering the stock in April 2022 priced at $12. It did rise to $15.21, but, subsequently, slid to $4.28 as the Federal Reserve hiked interest rates at such an aggressive pace only seen in the Paul Volcker Era. Trading at around $5 at the time of writing, the stock has u ...